CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. - Wikidata - wikimedia - TriplyDB

CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction.

CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction.

http://www.wikidata.org/entity/Q40418115

about

The cancer stem cell: evidence for its origin as an injured autoreactive T cell Pleiotropic Effects of IL-2 on Cancer: Its Role in Cervical Cancer To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses Pathways and therapeutic targets in melanoma T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy.Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1 Molecular pathways and therapeutic targets in lung cancer CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation.A soluble form of CTLA-4 is present in paediatric patients with acute lymphoblastic leukaemia and correlates with CD1d+ expression.64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues Modelling the spatial heterogeneity and molecular correlates of lymphocytic infiltration in triple-negative breast cancer.Effect of cytotoxic T-lymphocyte antigen-4, TNF-alpha polymorphisms on osteosarcoma: evidences from a meta-analysis.CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors.Association between CTLA-4 rs231775 polymorphism and risk of colorectal cancer: a meta analysis Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis.Positive and negative regulation of cellular immune responses in physiologic conditions and diseases Increased CTLA-4(+) T cells and an increased ratio of monocytes with loss of class II (CD14(+) HLA-DR(lo/neg)) found in aggressive pediatric sarcoma patients Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms.Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma Expression of membrane anchored cytokines and B7-1 alters tumor microenvironment and induces protective antitumor immunity in a murine breast cancer model.The role of the CTLA4 blockade in the treatment of malignant melanoma.Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma.Ctla-4 expression and polymorphisms in lung tissue of patients with diagnosed non-small-cell lung cancer.Anti-CTLA4 Antibody Clinical Trials in Melanoma.Genome-wide DNA methylation profile identified a unique set of differentially methylated immune genes in oral squamous cell carcinoma patients in India.Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function.Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model.Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers.Therapy for metastatic melanoma: an overview and update.Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer.Immunosuppressive microenvironment in neuroblastoma.Role of immunotherapy in the treatment of advanced non-small-cell lung cancer.Overcoming tumor-mediated immunosuppression.Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.Prospective Preliminary In Vitro Investigation of a Magnetic Iron Oxide Nanoparticle Conjugated with Ligand CD80 and VEGF Antibody As a Targeted Drug Delivery System for the Induction of Cell Death in Rodent Osteosarcoma Cells.ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer.

P2860

Q25256839-AAF82C32-E5BF-4D7E-ADB1-5367143405C9 Q26747008-F2F6C451-FD8F-4AE8-BA3A-65EBA0798D02 Q26767212-AF3C2193-71A6-4767-8D69-C55BE3B741D6 Q26865736-99E34C28-9139-4963-9F0D-EA3AF19CFD81 Q28074619-63508D04-8B7B-48AB-984B-70A3119B2D9D Q28076473-F13534E7-5620-4F7C-94BB-C65566D12AD3 Q30235105-517BDFA3-C4DB-4814-A787-64235381E63F Q33579883-25EB5887-54B7-449B-A1FF-99EDDBFB6369 Q33688872-671F26A9-3D27-4C4D-A99A-09875E279D54 Q33808334-22D478E3-4AA7-4DA8-9499-FFC5D97159F1 Q33849506-B6A5CBAC-3FA0-4C64-A7E3-DF7B7F735B1B Q34437911-E119B8D8-7494-4934-87A0-2EA55629D3A3 Q34443711-31B3CD6E-5C34-43B1-B679-03797B9F6357 Q35009369-17D9281C-6222-4233-8932-0404C4B2C585 Q35079792-28C8F0ED-FEF2-41B5-8862-3C1ADD055E9F Q35101747-70ED31D7-DD3A-4AAE-AD51-9018F41433F8 Q35173555-3B9D7CD3-CD99-434D-9170-048E10FD410B Q35783412-686567CF-D215-45C9-A00A-5DEF535EB9CD Q35883043-B6580CB7-452A-46CB-A51A-A1F0664B1C99 Q35965142-659DE07B-E88F-4B64-A270-8F9A789EEFC3 Q36067524-8294816C-8628-491F-ACB3-77525F9F9394 Q36699335-49029FC5-58FD-4523-BC8D-4F9C58457466 Q36940633-D9B79666-239A-49EA-BEDC-332E519D0D51 Q37008621-2807CE66-FA30-431D-B88F-B7F8293689D1 Q37012537-D2E945E7-DAB7-4E7D-8728-842614D9AE68 Q37044252-4CC34F33-4A14-4A2F-AAB2-2E669F9BF51E Q37234763-9C828BB5-6286-4FBF-9A4B-3233AAF1C985 Q37624648-F68CF766-349F-4291-89A8-65A1DA27A568 Q37697018-B164AECB-9644-43AA-A9F0-9281754E251C Q37706688-69F4A116-673F-4AE4-8DFD-106E5FECE04F Q37709496-4699FEA9-1575-41FD-8607-7343E6EB1483 Q37773244-7AFF93EB-D819-40D5-8F68-57AE82059253 Q37873464-37B56BC5-7883-4663-90EF-7C2398BF5D4C Q38002896-4CC85DEF-2B6C-464D-A850-23551F3A38BE Q38117379-40BC2996-77DD-4DD8-BED2-C43F74761435 Q38170384-50E72A34-DE26-4779-815B-ADA9BE298C8F Q38262255-6A27DF7E-FFBD-4AF6-9B5E-3DEAE5FA23D2 Q38549542-00022ABE-4F6A-4044-922C-8B22BBDBDF88 Q38731083-A80BB32C-1CF2-434D-8D12-2F2F661A7A0A Q38733611-009AEA4E-2B46-4D2A-B74A-9F4F8B79C03A

P2860

CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction.

http://www.wikidata.org/entity/Q40418115

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

CTLA-4 is constitutively expre ...... tosis upon ligand interaction.

@en

type

label

CTLA-4 is constitutively expre ...... tosis upon ligand interaction.

@en

prefLabel

CTLA-4 is constitutively expre ...... tosis upon ligand interaction.

@en

P1433

Q40418115-B8336FC4-C07D-4824-967A-D677E8751260

P1476

Q40418115-33493D71-A590-4D83-8B1A-50F1BF202666

P2093

Q40418115-15AE8793-4AF9-4147-845E-02536198E27D

Q40418115-41215BA7-E58A-4ADF-9F57-00CEAA17F17B

Q40418115-58E33B58-774E-4A7F-9246-B207A7175014

Q40418115-5D1C0A64-2D1B-4C8E-9D99-2CED538482F8

Q40418115-6912328E-49E3-402B-B1F2-D88402125F1D

Q40418115-920EA443-08D5-46FD-B4B4-FFEC2168822C

Q40418115-A1E29531-E664-45EF-BF29-713F46AE33DB

Q40418115-A9EBDFA0-34B1-4B67-8CC9-15DC4B304A2F

Q40418115-B442C179-BA65-40A0-8E38-6F550C8E538D

Q40418115-B6CF73ED-3F00-400E-82D2-AADACA73ED23

P2860

Q40418115-972F5A35-20F9-44B1-AF22-D5E644144FA5

Q40418115-9BDF70C1-80E8-4229-956D-1F00C6DB18B4

Q40418115-C4E4DA30-F000-4972-8BF3-62A02E02412B

P304

Q40418115-3DA1E729-0D86-4E25-960E-659E74580D69

P31

Q40418115-1FFCEF40-382E-4491-9635-4606D76F57D8

P356

Q40418115-1CC405FA-E64B-48D8-A1EE-A94802CE776C

P433

Q40418115-8A538645-41C8-4288-881B-AB0CDAB1EBD7

P478

Q40418115-D5B05A6B-A19D-44E0-A484-9FAF791F8280

P50

Q40418115-4ACB3E46-D486-4DD6-9260-C0372E9E9EC4

Q40418115-5BDBEB1C-C75B-4901-89A1-FBA9AD138A52

Q40418115-AC9E44FC-B64A-451E-8552-1B85CA08FF19

Q40418115-CD834027-6DC3-4235-9FF9-4E75D6CDB240

Q40418115-DEE8D785-94FD-4168-84CF-09E9EBD7B9BC

Q40418115-F2E521F5-612B-47A8-A816-262092B9946A

P577

Q40418115-7794F4B8-A60A-4B0E-B1B6-A1F1C5AB363F

P5875

Q40418115-AEE116C1-AD81-4491-91EB-564D6CC03C31

P698

Q40418115-6D47258A-074C-4154-BED0-A74116A2C3C5

P921

Q40418115-69C6E584-A590-4C38-BCEF-8D9217B8ACF4

P356

P1433

International Journal of Cancer

P1476

CTLA-4 is constitutively expre ...... tosis upon ligand interaction.

@en

P2093

Alberto M Martelli

http://www.w3.org/2001/XMLSchema#string

Elisabetta Contardi

http://www.w3.org/2001/XMLSchema#string

Federica Falà

http://www.w3.org/2001/XMLSchema#string

Francesca Ricci

http://www.w3.org/2001/XMLSchema#string

Giovanni Battista Ferrara

http://www.w3.org/2001/XMLSchema#string

Giulio L Palmisano

http://www.w3.org/2001/XMLSchema#string

Marco Alberghini

http://www.w3.org/2001/XMLSchema#string

Maria Pia Pistillo

http://www.w3.org/2001/XMLSchema#string

Pier Luigi Tazzari

http://www.w3.org/2001/XMLSchema#string

Sandra Salvi

http://www.w3.org/2001/XMLSchema#string

P2860

Structural analysis of CTLA-4 function in vivo

Immunotoxins containing recombinant anti-CTLA-4 single-chain fragment variable antibodies and saporin: in vitro results and in vivo effects in an acute rejection model.

Vaccination with mouse mammary adenocarcinoma cells coexpressing B7-1 (CD80) and B7-2 (CD86) discloses the dominant effect of B7-1 in the induction of antitumor immunity.

P304

538-550

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.21155

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Stefano Mantero

Enrico Lucarelli

Andrea Bolognesi

Davide Maria Donati

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7828258

http://www.w3.org/2001/XMLSchema#string

P698

15912538

http://www.w3.org/2001/XMLSchema#string

P921

apoptotic process